Pfizer’s Pediatric Hemophilia Approval Shows Where the Market Is Moving
Pfizer has received U.S. FDA approval to expand the use of Hympavzi (marstacimab) for pediatric patients with hemophilia A and B, marking an important milestone in the shift toward non-factor therapies. The expanded indication includes children aged 6–11 years with or without inhibitors and broadens access for patients aged 12 years and older with inhibitors. This approval highlights the growing demand for convenient, once-weekly subcutaneous treatments that reduce bleeding episodes, improve quality of life, and address the challenges of traditional factor replacement therapy. The announcement also reflects broader trends shaping the global hemophilia treatment market, including personalized prophylaxis, inhibitor management, extended half-life therapies, gene therapy, and real-world evidence.
Jul 1, 2026
